Knockdown of the cochaperone SGTA results in the suppression of androgen and PI3K/Akt signaling and inhibition of prostate cancer cell proliferation

International Journal of Cancer

Volumn 133, Issue 12, 2013, Pages 2812-2823

  Trotta, Andrew P ^a   Need, Eleanor F ^a   Selth, Luke A ^a   Chopra, Samarth ^b,c   Pinnock, Carole B ^b   Leach, Damien A ^a   Coetzee, Gerhard A ^d   Butler, Lisa M ^a   Tilley, Wayne D ^a   Buchanan, Grant ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b REPATRIATION GENERAL HOSPITAL   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

androgen signaling; kinase signaling; tetratricopeptide repeat cochaperones

Indexed keywords

ANDROGEN; ANDROSTANOLONE; CHAPERONE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; SMALL GLUTAMINE RICH TETRATICOPEPTIDE REPEAT CONTAINING PROTEIN ALPHA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE CONTROL; GENE EXPRESSION PROFILING; GENE SILENCING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; SIGNAL TRANSDUCTION;

ANDROGEN SIGNALING; KINASE SIGNALING; TETRATRICOPEPTIDE REPEAT COCHAPERONES;

ANIMALS; CARRIER PROTEINS; CELL PROLIFERATION; DIHYDROTESTOSTERONE; HUMANS; MALE; MICE; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TRANSCRIPTOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84885614687     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28310     Document Type: Article

References (45)

1. Balch WE, Morimoto RI, Dillin A, et al. Adapting proteostasis for disease intervention. Science 2008; 319: 916-19.
2. Taipale M, Jarosz DF, Lindquist S,. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 2010; 11: 515-28.
3. Dai C, Whitesell L, Rogers AB, et al. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 2007; 130: 1005-18.
4. Trepel J, Mollapour M, Giaccone G, et al. Targeting the dynamic HSP90 complex in cancer. Nat Rev 2010; 10: 537-49.
5. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
6. Centenera MM, Gillis JL, Hanson AR, et al. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clin Cancer Res 2012; 18: 3562-70.
7. Kumano M, Furukawa J, Shiota M, et al. Cotargeting stress-activated hsp27 and autophagy as a combinatorial strategy to amplify endoplasmic reticular stress in prostate cancer. Mol Cancer Ther 2012; 11: 1661-71.
8. Rocchi P, So A, Kojima S, et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 2004; 64: 6595-602.
9. Whitesell L, Lindquist SL,. HSP90 and the chaperoning of cancer. Nat Rev 2005; 5: 761-72.
10. Cardillo MR, Ippoliti F,. IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis. Anticancer Res 2006; 26: 3409-16.
11. Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003; 425: 407-10.
12. Smith DF, Toft DO,. Minireview: The intersection of steroid receptors with molecular chaperones: observations and questions. Mol Endocrinol (Baltimore, MD) 2008; 22: 2229-40.
13. Cheung-Flynn J, Prapapanich V, Cox MB, et al. Physiological role for the cochaperone FKBP52 in androgen receptor signaling. Mol Endocrinol (Baltimore, MD) 2005; 19: 1654-66.
14. Yong W, Yang Z, Periyasamy S, et al. Essential role for co-chaperone Fkbp52 but not Fkbp51 in androgen receptor-mediated signaling and physiology. J Biol Chem 2007; 282: 5026-36.
15. Schulke JP, Wochnik GM, Lang-Rollin I, et al. Differential impact of tetratricopeptide repeat proteins on the steroid hormone receptors. PLoS One 2010; 5: e11717.
16. Buchanan G, Ricciardelli C, Harris JM, et al. Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha. Cancer Res 2007; 67: 10087-96.
17. Trotta AP, Need EF, Butler LM, et al. Subdomain structure of the co-chaperone SGTA and activity of its androgen receptor client. J Mol Endocrinol 2012; 49: 57-68.
18. Yin H, Wang H, Zong H, et al. SGT, a Hsp90β binding partner, is accumulated in the nucleus during cell apoptosis. Biochem Biophys Res Commun 2006; 343: 1153-8.
19. Winnefeld M, Rommelaere J, Cziepluch C,. The human small glutamine-rich TPR-containing protein is required for progress through cell division. Exp Cell Res 2004; 293: 43-57.
20. Cziepluch C, Kordes E, Poirey R, et al. Identification of a novel cellular TPR-containing protein, SGT, that interacts with the nonstructural protein NS1 of parvovirus H-1. J Virol 1998; 72: 4149-56.
21. Cziepluch C, Lampel S, Grewenig A, et al. H-1 parvovirus-associated replication bodies: a distinct virus-induced nuclear structure. J Virol 2000; 74: 4807-15.
22. Winnefeld M, Grewenig A, Schnolzer M, et al. Human SGT interacts with Bag-6/Bat-3/Scythe and cells with reduced levels of either protein display persistence of few misaligned chromosomes and mitotic arrest. Exp Cell Res 2006; 312: 2500-14.
23. Schantl JA, Roza M, De Jong AP, et al. Small glutamine-rich tetratricopeptide repeat-containing protein (SGT) interacts with the ubiquitin-dependent endocytosis (UbE) motif of the growth hormone receptor. Biochem J 2003; 373: 855-63.
24. Moritz A, Li Y, Guo A, et al. Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases. Sci Signal 2010; 3: ra64.
25. Wu HC, Hsieh JT, Gleave ME, et al. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 1994; 57: 406-12.
26. Need EF, Scher HI, Peters AA, et al. A novel androgen receptor amino terminal region reveals two classes of amino/carboxyl interaction-deficient variants with divergent capacity to activate responsive sites in chromatin. Endocrinology 2009; 150: 2674-82.
27. Smyth G,. Limma: linear models for microarray data. New York: Springer, 2005.
28. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-50.
29. Huang da W, Sherman BT, Lempicki RA,. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57.
30. Jackson AL, Linsley PS,. Noise amidst the silence: off-target effects of siRNAs? Trends Genet 2004; 20: 521-4.
31. Jia L, Berman BP, Jariwala U, et al. Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS One 2008; 3: e3645.
32. Jiang X, Chen S, Asara JM, et al. Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110β and p110δ catalytic subunits. J Biol Chem 2010; 285: 14980-9.
33. Vivanco I, Sawyers CL,. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev 2002; 2: 489-501.
34. Li L, Ittmann MM, Ayala G, et al. The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis 2005; 8: 108-18.
35. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11-22.
36. Sarker D, Reid AH, Yap TA, et al. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 2009; 15: 4799-805.
37. Scher HI, Sawyers CL,. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23: 8253-61.
38. Prescott J, Coetzee GA,. Molecular chaperones throughout the life cycle of the androgen receptor. Cancer Lett 2006; 231: 12-19.
39. Shen MM, Abate-Shen C,. Pten inactivation and the emergence of androgen-independent prostate cancer. Cancer Res 2007; 67: 6535-8.
40. Ha S, Ruoff R, Kahoud N, et al. Androgen receptor levels are upregulated by Akt in prostate cancer. Endocr Relat Cancer 2011; 18: 245-55.
41. Zhu Q, Youn H, Tang J, et al. Phosphoinositide 3-OH kinase p85α and p110β are essential for androgen receptor transactivation and tumor progression in prostate cancers. Oncogene 2008; 27: 4569-79.
42. Liu FH, Wu SJ, Hu SM, et al. Specific interaction of the 70-kDa heat shock cognate protein with the tetratricopeptide repeats. J Biol Chem 1999; 274: 34425-32.
43. Periyasamy S, Hinds T, Jr, Shemshedini L, et al. FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A. Oncogene 2010; 29: 1691-701.
44. Periyasamy S, Warrier M, Tillekeratne MP, et al. The immunophilin ligands cyclosporin A and FK506 suppress prostate cancer cell growth by androgen receptor-dependent and -independent mechanisms. Endocrinology 2007; 148: 4716-26.
45. Horibe T, Kohno M, Haramoto M, et al. Designed hybrid TPR peptide targeting Hsp90 as a novel anticancer agent. J Transl Med 2011; 9: 8.